New Trends in Chemotherapy of Tumors

  • W. Wilmanns
  • C. Clemm
  • H. Gerhartz
  • K. Possinger
  • H. Sauer
Conference paper


Chemotherapy of tumors is not a new treatment; it is rather an established treatment in which some new trends have appeared during the past 10 years. It must be regarded as a part of an interdisciplinary conducted treatment modality applied in any neoplastic disease.


Acute Lymphoblastic Leukemia Remission Rate Testicular Cancer Autologous Bone Marrow Transplantation Nonseminomatous Germ Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bertino JR (1987) Adjuvant therapy of osteosarcoma. J Clin Oncol 5:831–832PubMedGoogle Scholar
  2. Bonadonna G, Valagussa P (1987) Current status of adjuvant chemotherapy for breast cancer. Semin Oncol 14:8–22PubMedGoogle Scholar
  3. Brandt StJ, Peters WP, Atwater SK, et al (1988) Effect of recombinant human granulocyte-macro-phage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876PubMedCrossRefGoogle Scholar
  4. Brunner KW (1987) Palliative Tumor-Chemotherapie und Lebensqualität: was ist optimal? Schweiz Med Wochenschr 117:688–692PubMedGoogle Scholar
  5. Champlin R, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562PubMedGoogle Scholar
  6. Clemm C, Hartenstein R, Willich N, Boening L, Wilmanns W (1986) Vinblastine, ifosfamide, cisplatin treatment of bulky seminoma. Cancer 58:2203–2207PubMedCrossRefGoogle Scholar
  7. Clemm C, Hartenstein R, Mair W, Wiesel N, Ledderose G (1988) Vierfach-Kombination beim nichtseminomatösen Hodentumor mit ungünstiger Prognose. In: Schmoll HJ, Weißbach L (eds) Diagnostik und Therapie von Hodentumoren. Springer, Berlin Heidelberg New York, pp 212–221Google Scholar
  8. Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275–3280PubMedGoogle Scholar
  9. Einhorn LH (1987) Chemotherapy of disseminated germ cell tumors. Cancer 60:570–573PubMedCrossRefGoogle Scholar
  10. Frei E (1985) Curative cancer chemotherapy. Cancer Res 45:6523–6537PubMedGoogle Scholar
  11. Gale RP, Foon KA (1986) Acute myeloid leukemia: recent advances in therapy. Clin Lab Haematol 15:781–810Google Scholar
  12. Gerhartz HH, Thiel E, Hiller E, Nerl C, Wilmanns W, Huhn D für die Münchner Lymphomgruppe (1986) Vergleich der CHOP- und COP-BLAM-Chemotherapie hochmaligner Non-Hodgkin-Lymphome. Dtsch Med Wochenschr 111:1511–1515PubMedCrossRefGoogle Scholar
  13. Gerhartz HH, Thiel E, Brittinger G, et al (NHL Study Group) (1988) German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/-IMVP-16 chemotherapy with randomized adjuvant radiotherapy. Blut 56:139–142PubMedCrossRefGoogle Scholar
  14. Hartenstein R, Clemm C, Jäckel R, Wilmanns W (1988) Prognostische Kriterien beim nicht-semino-matösen Hodenkarzinomen: retrospektive Analyse 1979–1985. In: Schmoll HJ, Weissbach L (eds) Springer, Berlin Heidelberg New York, pp 111–124Google Scholar
  15. Hoelzer D, Gale RP (1987) Acute lymphoblastic leukemia in adults: recent progress, future directions. Semin Hematol 24:27–39PubMedGoogle Scholar
  16. Jehn U, Knüppel W, Wilmanns W (1988) Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial. Onkologie 11:13–17PubMedCrossRefGoogle Scholar
  17. Kaufmann M, Jonat W, Maass H (1986) Adjuvante Hormon- und Chemotherapie beim Mammakarzinom. Dtsch Arztebl 83:248–250Google Scholar
  18. Lippman ME (1985) The NIH consensus development conference on adjuvant chemotherapy for breast cancer — a commentary. Breast Cancer Res Treat 6:195–200PubMedCrossRefGoogle Scholar
  19. Loeffler M, Pfreundschuh M, Hasenclever D, Hiller E, Gerhartz HH, Wilmanns W, et al (1988) Prognostic risk factors in advanced Hodgkin’s lymphoma. Report of the German Hodgkin Study Group. Blut 56:273–281PubMedCrossRefGoogle Scholar
  20. Morstyn G, Souza LM, Keech J, Sheridan W, et al (1988) Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 667–671Google Scholar
  21. Pfreundschuh M, Schaadt M, Diehl V (1986) Chemotherapie der Non-Hodgkin-Lymphome. Internist (Berlin) 27:506–524Google Scholar
  22. Pfreundschuh M, Schaadt M, Diehl V, et al (1986) Hodgkin-Lymphoma im Erwachsenenalter. Dtsch Arztebl 83:2538–2540Google Scholar
  23. Possinger K, Sauer H-J, Wilmanns W (1988) Chemotherapie metastasierter Mammakarzinome. Dtsch Med Wochenschr 113:224–231PubMedCrossRefGoogle Scholar
  24. Sauer H-J, Wilmanns W (1985) Internistische Therapie maligner Erkrankungen, 2nd edn. Urban and Schwarzenberg, MunichGoogle Scholar
  25. Schmoll HJ, Weissbach L (eds) (1988) Diagnostik und Therapie von Hodentumoren. Springer, Berlin Heidelberg New YorkGoogle Scholar
  26. Wilmanns W (1987) Dem Patienten niemals die Hoffnung nehmen! Internistische Behandlung maligner Tumoren unter Berücksichtigung der Lebensqualität. Dtsch Arztbl 84:2261–2263Google Scholar
  27. Wilmanns W (1989) Adjuvante Therapie beim Mammakarzinom. Aktueller Stand der adjuvanten Chemotherapie. In: Bohmert H (ed) Brustkrebs. Organerhaltung und Rekonstruktion. Thieme, Stuttgart, pp 496–502Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • W. Wilmanns
  • C. Clemm
  • H. Gerhartz
  • K. Possinger
  • H. Sauer

There are no affiliations available

Personalised recommendations